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Introduction {#jdi12067-sec-0001}
============

Genetic, environmental and demographic factors, and their interaction, determine an individual\'s risk for type 2 diabetes; its heritability has been estimated as approximately 25%[1](#jdi12067-bib-0001){ref-type="ref"}. Despite considerable concerted efforts over the past 15 years, it is only in the past 5 years that substantial progress has been made in identifying genetic variants robustly associated with type 2 diabetes, largely as a result of technological advances[2](#jdi12067-bib-0002){ref-type="ref"}. In particular, the advent of genome‐wide association (GWA) studies involving several thousands of samples has facilitated this progress. This approach is to search for susceptibility variants across the entire genome in an unbiased, hypothesis‐free manner.

The alleles or mutations responsible for rare monogenic forms of diabetes, including maturity onset diabetes of the young (MODY), were relatively easily identified through family‐based linkage analyses[3](#jdi12067-bib-0003){ref-type="ref"}. These discoveries then led to molecular diagnostics of the diseases with demonstrable prognostic and therapeutic relevance. Although similar approaches have been applied to common forms of type 2 diabetes, the multifactorial nature has rendered the identification of genetic variants an enormous challenge. In consideration of its low penetrance, it was proposed that association analyses in large unrelated sample sets should be more powerful in susceptibility gene discovery for type 2 diabetes than family‐based linkage approaches[4](#jdi12067-bib-0004){ref-type="ref"}.

The association signal can be detected only if one examines the causal variant itself or a nearby marker with which it is tightly correlated; therefore, researchers were obliged to direct their attention to particular candidate gene variants of interest until the advent of GWA studies. Among a number of candidate genes thus interrogated, common coding variants in *PPARG*[5](#jdi12067-bib-0005){ref-type="ref"} and *KCNJ11/ABCC8*[6](#jdi12067-bib-0006){ref-type="ref"} were shown to be associated with type 2 diabetes. In 2006, without prior knowledge of biology, *TCF7L2* was first discovered to be a susceptibility gene after systematic association analysis across a 10.5‐Mb region of previously reported linkage[7](#jdi12067-bib-0007){ref-type="ref"}. Subsequently, in 2007, the first wave of GWA studies identified six novel loci in populations of European descent[8](#jdi12067-bib-0008){ref-type="ref"}. Successive rounds of GWA studies and meta‐analyses have brought the number of confirmed common variants associated with type 2 diabetes to approximately 70[9](#jdi12067-bib-0009 jdi12067-bib-0010 jdi12067-bib-0011 jdi12067-bib-0012 jdi12067-bib-0013 jdi12067-bib-0014 jdi12067-bib-0015 jdi12067-bib-0016 jdi12067-bib-0017 jdi12067-bib-0018 jdi12067-bib-0019 jdi12067-bib-0020 jdi12067-bib-0021 jdi12067-bib-0022 jdi12067-bib-0023 jdi12067-bib-0024 jdi12067-bib-0025 jdi12067-bib-0026){ref-type="ref"}, and have also discovered \>40 common variants influencing normal physiological variation in continuous glycemic measures (e.g., fasting glucose and insulin)[12](#jdi12067-bib-0012 jdi12067-bib-0027 jdi12067-bib-0028 jdi12067-bib-0029 jdi12067-bib-0030 jdi12067-bib-0031 jdi12067-bib-0032){ref-type="ref"} to date.

In the present article, the evidence in favor of a genetic basis for type 2 diabetes, focusing specifically on the DNA sequence variants that have been implicated in risk predisposition and the assumed clinical implications of genomics, are reviewed.

Discovery of Susceptibility Gene Variants for Type 2 Diabetes {#jdi12067-sec-0002}
=============================================================

Largely through GWA studies, the number of loci robustly implicated in type 2 diabetes risk; that is, those that have attained a genome‐wide significance level (*P *\<* *5 × 10^−8^) and also have been repeatedly validated in independent samples, has climbed from just three -- *PPARG*,*KCNJ11/ABCC8* and *TCF7L2* -- in 2006 to approximately 70 today (Table [1](#jdi12067-tbl-0001){ref-type="table-wrap"}).

###### List of susceptibility loci for type 2 diabetes with significant evidence for association (*P *\<* *5E‐8)

  Mapped gene(s)[a](#jdi12067-note-0001){ref-type="fn"}   Reported gene(s)[a](#jdi12067-note-0001){ref-type="fn"}   Lead SNP     Region     Pos (GRCh37)   Risk allele   RAF in controls   *P*‐value   Reported study[b](#jdi12067-note-0002){ref-type="fn"}       OR \[95% CI\]         First‐reported ethnic group[c](#jdi12067-note-0003){ref-type="fn"}
  ------------------------------------------------------- --------------------------------------------------------- ------------ ---------- -------------- ------------- ----------------- ----------- ----------------------------------------------------------- --------------------- --------------------------------------------------------------------
  NOTCH2/ADAM30                                           NOTCH2                                                    rs10923931   1p12       120517959      T             0.11              4.E‐08      Zeggini *et al*.[9](#jdi12067-bib-0009){ref-type="ref"}     1.13 \[1.08‐1.17\]    European descent
  RPL31P13/PROX1                                          PROX1                                                     rs340874     1q32.3     214159256      C             0.54              7.E‐10      Dupuis *et al*.[12](#jdi12067-bib-0012){ref-type="ref"}     1.07 \[1.05‐1.09\]    European descent
  GCKR                                                    GCKR                                                      rs780094     2p23.3     27741237       C             0.60              1.E‐09      Dupuis *et al*.[12](#jdi12067-bib-0012){ref-type="ref"}     1.06 \[1.04‐1.08\]    European descent
  THADA                                                   THADA                                                     rs7578597    2p21       43732823       T             0.90              1.E‐09      Zeggini *et al*.[9](#jdi12067-bib-0009){ref-type="ref"}     1.15 \[1.10‐1.20\]    European descent
  EIF3FP3/BCL11A                                          BCL11A                                                    rs243021     2p16.1     6058481        A             0.48              3.E‐15      Voight *et al*.[15](#jdi12067-bib-0015){ref-type="ref"}     1.08 \[1.06‐1.10\]    European descent
  TMEM163                                                 TMEM163                                                   rs998451     2q21.3     135429288      G             0.86              6.E‐12      Tabassum *et al*.[25](#jdi12067-bib-0025){ref-type="ref"}   1.56 \[1.38‐1.77\]    South Asian
  RND3/FABP5P10                                           RND3                                                      rs7560163    2q23.3     151637936      C             0.86              7.E‐09      Palmer *et al*.[21](#jdi12067-bib-0021){ref-type="ref"}     1.33 \[1.19‐1.49\]    African American
  RBMS1                                                   RBMS1/ITGB6                                               rs7593730    2q24.2     161171454      C             0.78              4.E‐08      Qi *et al*.[16](#jdi12067-bib-0016){ref-type="ref"}         1.11 \[1.08‐1.16\]    European descent
  GRB14/COBLL1                                            GRB14                                                     rs3923113    2q24.3     165501849      A             0.74              1.E‐08      Kooner *et al*.[19](#jdi12067-bib-0019){ref-type="ref"}     1.09 \[1.06‐1.13\]    South Asian
  KIAA1486/IRS1                                           IRS1                                                      rs7578326    2q36.3     227020653      A             0.65              5.E‐20      Voight *et al*.[15](#jdi12067-bib-0015){ref-type="ref"}     1.11 \[1.08‐1.13\]    European descent
  TIMP4/GSTM5P1[d](#jdi12067-note-0004){ref-type="fn"}    PPARG                                                     rs13081389   3p25.2     12289800       A             0.96              2.E‐07      Voight *et al*.[15](#jdi12067-bib-0015){ref-type="ref"}     1.24 \[1.15‐1.35\]    European descent
  PSMD6/PRICKLE2                                          PSMD6                                                     rs831571     3p14.1     64048297       C             0.61              8.E‐11      Cho *et al*.[20](#jdi12067-bib-0020){ref-type="ref"}        1.09 \[1.06--1.12\]   East Asian
  ADAMTS9/MAGI1                                           ADAMTS9                                                   rs4607103    3p14.1     64711904       C             0.76              1.E‐08      Zeggini *et al*.[9](#jdi12067-bib-0009){ref-type="ref"}     1.09 \[1.06‐1.12\]    European descent
  ADCY5                                                   ADCY5                                                     rs11708067   3q21.1     123065778      A             0.78              1.E‐20      Dupuis *et al*.[12](#jdi12067-bib-0012){ref-type="ref"}     1.12 \[1.09‐1.15\]    European descent
  IGF2BP2                                                 IGF2BP2                                                   rs4402960    3q27.2     185511687      T             0.31              3.E‐09      Perry *et al*.[22](#jdi12067-bib-0022){ref-type="ref"}      1.15 \[1.10‐1.21\]    European descent
  ST6GAL1                                                 ST6GAL1                                                   rs16861329   3q27.3     186666461      G             0.75              3.E‐08      Kooner *et al*.[19](#jdi12067-bib-0019){ref-type="ref"}     1.09 \[1.06‐1.12\]    South Asian
  WFS1                                                    WFS1                                                      rs1801214    4p16.1     6303022        T             0.73              3.E‐08      Voight *et al*.[15](#jdi12067-bib-0015){ref-type="ref"}     1.13 \[1.08‐1.18\]    European descent
  MAEA                                                    MAEA                                                      rs6815464    4p16.3     1309901        C             0.58              2.E‐20      Cho *et al*.[20](#jdi12067-bib-0020){ref-type="ref"}        1.13 \[1.10--1.16\]   East Asian
  ANKRD55                                                 ANKRD55                                                   rs459193     5q11.2     55806751       G             0.70              6.E‐09      Morris *et al*.[24](#jdi12067-bib-0024){ref-type="ref"}     1.08 \[1.05--1.11\]   European descent
  SNORA47/PDE8B                                           ZBED3                                                     rs4457053    5q13.3     76424949       G             0.26              3.E‐12      Voight *et al*.[15](#jdi12067-bib-0015){ref-type="ref"}     1.08 \[1.06‐1.11\]    European descent
  CDKAL1                                                  CDKAL1                                                    rs7766070    6p22.3     20686573       A             0.27              6.E‐11      Perry *et al*.[22](#jdi12067-bib-0022){ref-type="ref"}      1.21 \[1.14‐1.28\]    European descent
  ZFAND3                                                  ZFAND3                                                    rs9470794    6p21.2     38106844       C             0.27              2.E‐10      Cho *et al*.[20](#jdi12067-bib-0020){ref-type="ref"}        1.12 \[1.08--1.16\]   East Asian
  KCNK16/KCNK17                                           KCNK16                                                    rs1535500    6p21.2     39284050       T             0.42              2.E‐08      Cho *et al*.[20](#jdi12067-bib-0020){ref-type="ref"}        1.08 \[1.05--1.11\]   East Asian
  C6orf57                                                 C6orf57                                                   rs1048886    6q13       71289189       G             0.18              3.E‐08      Sim *et al*.[18](#jdi12067-bib-0018){ref-type="ref"}        1.54 \[1.32‐1.80\]    Asian Indian
  EEF1A1P26/TMEM195                                       DGKB                                                      rs2191349    7p21.2     15064309       T             0.56              1.E‐08      Dupuis *et al*.[12](#jdi12067-bib-0012){ref-type="ref"}     1.06 \[1.04‐1.08\]    European descent
  JAZF1                                                   JAZF1                                                     rs849134     7p15.1     28196222       A             0.53              3.E‐09      Voight *et al*.[15](#jdi12067-bib-0015){ref-type="ref"}     1.13 \[1.09‐1.18\]    European descent
  GCK/YKT6                                                GCK                                                       rs4607517    7p13       44235668       A             0.22              5.E‐08      Dupuis *et al*.[12](#jdi12067-bib-0012){ref-type="ref"}     1.07 \[1.05‐1.10\]    European descent
  ZNF800/GCC1                                             GCC1/PAX4                                                 rs6467136    7q32.1     127164958      G             0.79              5.E‐11      Cho *et al*.[20](#jdi12067-bib-0020){ref-type="ref"}        1.11 \[1.07--1.14\]   East Asian
  KLF14/FLJ43663                                          KLF14                                                     rs972283     7q32.3     130466854      G             0.55              2.E‐10      Voight *et al*.[15](#jdi12067-bib-0015){ref-type="ref"}     1.07 \[1.05‐1.10\]    European descent
  ANK1                                                    ANK1                                                      rs516946     8p11.1     41519248       C             0.76              3.E‐10      Morris *et al*.[24](#jdi12067-bib-0024){ref-type="ref"}     1.09 \[1.06--1.12\]   European descent
  TP53INP1                                                TP53INP1                                                  rs896854     8q22.1     95960511       T             0.44              1.E‐09      Voight *et al*.[15](#jdi12067-bib-0015){ref-type="ref"}     1.06 \[1.04‐1.09\]    European descent
  SLC30A8                                                 SLC30A8                                                   rs3802177    8q24.11    118185025      G             0.76              1.E‐08      Voight *et al*.[15](#jdi12067-bib-0015){ref-type="ref"}     1.15 \[1.10‐1.21\]    European descent
  UBA52P6/DMRTA1                                          CDKN2A/2B                                                 rs10965250   9p21.3     22133284       G             0.81              1.E‐10      Voight *et al*.[15](#jdi12067-bib-0015){ref-type="ref"}     1.20 \[1.13‐1.27\]    European descent
  PTPRD                                                   PTPRD                                                     rs17584499   9p24.1     8879118        T             0.06              9.E‐10      Tsai *et al*.[13](#jdi12067-bib-0013){ref-type="ref"}       1.57 \[1.36‐1.82\]    Han Chinese
  GLIS3                                                   GLIS3                                                     rs7041847    9p24.2     4287466        A             0.41              2.E‐14      Cho *et al*.[20](#jdi12067-bib-0020){ref-type="ref"}        1.10 \[1.07--1.13\]   East Asian
  KRT18P24/CHCHD9                                         TLE4                                                      rs13292136   9q21.31    81952128       C             0.93              3.E‐08      Voight *et al*.[15](#jdi12067-bib-0015){ref-type="ref"}     1.11 \[1.07‐1.15\]    European descent
  TLE1                                                    TLE1                                                      rs2796441    9q21.32    84308948       G             0.57              5.E‐09      Morris *et al*.[24](#jdi12067-bib-0024){ref-type="ref"}     1.07 \[1.05--1.10\]   European descent
  CDC123/CAMK1D                                           CDC123                                                    rs12779790   10p13      12328010       G             0.18              1.E‐10      Zeggini *et al*.[9](#jdi12067-bib-0009){ref-type="ref"}     1.11 \[1.07‐1.14\]    European descent
  VPS26A                                                  VPS26A                                                    rs1802295    10q22.1    70931474       A             0.26              4.E‐08      Kooner *et al*.[19](#jdi12067-bib-0019){ref-type="ref"}     1.08 \[1.05‐1.12\]    South Asian
  ZMIZ1                                                   ZMIZ1                                                     rs12571751   10q22.3    80942631       A             0.52              1.E‐10      Morris *et al*.[24](#jdi12067-bib-0024){ref-type="ref"}     1.08 \[1.05--1.10\]   European descent
  HHEX/EXOC6                                              HHEX                                                      rs5015480    10q23.33   94465559       C             0.57              2.E‐09      Perry *et al*.[22](#jdi12067-bib-0022){ref-type="ref"}      1.18 \[1.11‐1.23\]    European descent
  TCF7L2                                                  TCF7L2                                                    rs7903146    10q25.2    114758349      T             0.29              2.E‐40      Perry *et al*.[22](#jdi12067-bib-0022){ref-type="ref"}      1.58 \[1.47‐1.68\]    European descent
  GRK5                                                    GRK5                                                      rs10886471   10q26.11   121149403      C             0.78              7.E‐09      Li *et al*.[26](#jdi12067-bib-0026){ref-type="ref"}         1.12 \[1.08‐1.16\]    Chinese
  KCNQ1[e](#jdi12067-note-0005){ref-type="fn"}            KCNQ1                                                     rs231362     11p15.5    2691471        G             0.52              3.E‐13      Voight *et al*.[15](#jdi12067-bib-0015){ref-type="ref"}     1.08 \[1.06‐1.10\]    European descent
  KCNQ1                                                   KCNQ1 (OT1)                                               rs2237895    11p15.4    2857194        C             0.33              1.E‐09      Tsai *et al*.[13](#jdi12067-bib-0013){ref-type="ref"}       1.29 \[1.19‐1.40\]    Japanese/Han Chinese
  KCNJ11/ABCC8                                            KCNJ11                                                    rs5219       11p15.1    17408630       C             0.40              7.E‐11      Zeggini *et al*.[33](#jdi12067-bib-0033){ref-type="ref"}    1.14 \[1.10‐1.19\]    European descent
  ARAP1                                                   ARAP1                                                     rs1552224    11q13.4    72433098       A             0.87              1.E‐22      Voight *et al*.[15](#jdi12067-bib-0015){ref-type="ref"}     1.14 \[1.11‐1.17\]    European descent
  RPS3AP42/MTNR1B                                         MTNR1B                                                    rs1387153    11q14.3    92673828       T             0.28              8.E‐15      Voight *et al*.[15](#jdi12067-bib-0015){ref-type="ref"}     1.09 \[1.06‐1.11\]    European descent
  KLHDC5                                                  KLHDC5                                                    rs10842994   12p11.22   27965150       C             0.80              6.E‐10      Morris *et al*.[24](#jdi12067-bib-0024){ref-type="ref"}     1.10 \[1.06--1.13\]   European descent
  RPSAP52                                                 RPSAP52                                                   rs1531343    12q14.3    66174894       C             0.12              4.E‐09      Voight *et al*.[15](#jdi12067-bib-0015){ref-type="ref"}     1.10 \[1.07‐1.14\]    European descent
  TSPAN8/LGR5                                             TSPAN8                                                    rs7961581    12q21.1    71663102       C             0.27              1.E‐09      Zeggini *et al*.[9](#jdi12067-bib-0009){ref-type="ref"}     1.09 \[1.06‐1.12\]    European descent
  OASL                                                    OASL                                                      rs7957197    12q24.31   121460686      T             0.85              2.E‐08      Voight *et al*.[15](#jdi12067-bib-0015){ref-type="ref"}     1.07 \[1.05‐1.10\]    European descent
  NDFIP2/SPRY2                                            SPRY2                                                     rs1359790    13q31.1    80717156       G             0.71              6.E‐09      Shu *et al*.[14](#jdi12067-bib-0014){ref-type="ref"}        1.15 \[1.10‐1.20\]    Chinese
  RASGRP1                                                 RASGRP1                                                   rs7403531    15q14      38822905       T             0.35              4.E‐09      Li *et al*.[26](#jdi12067-bib-0026){ref-type="ref"}         1.10 \[1.06‐1.13\]    Chinese
  C2CD4A/C2CD4B                                           C2CD4A/4B                                                 rs7172432    15q22.2    62396389       A             0.58              9.E‐14      Yamauchi *et al*.[17](#jdi12067-bib-0017){ref-type="ref"}   1.11 \[1.08‐1.14\]    Japanese
  HMG20A                                                  HMG20A                                                    rs7178572    15q24.3    77747190       G             0.52              7.E‐11      Kooner *et al*.[19](#jdi12067-bib-0019){ref-type="ref"}     1.09 \[1.06--1.12\]   South Asian
  ZFAND6/FAH                                              ZFAND6                                                    rs11634397   15q25.1    80432222       G             0.64              2.E‐09      Voight *et al*.[15](#jdi12067-bib-0015){ref-type="ref"}     1.06 \[1.04‐1.08\]    European descent
  AP3S2                                                   AP3S2                                                     rs2028299    15q26.1    90374257       C             0.31              2.E‐11      Kooner *et al*.[19](#jdi12067-bib-0019){ref-type="ref"}     1.10 \[1.07‐1.13\]    South Asian
  PRC1                                                    PRC1                                                      rs8042680    15q26.1    91521337       A             0.22              2.E‐10      Voight *et al*.[15](#jdi12067-bib-0015){ref-type="ref"}     1.07 \[1.05‐1.09\]    European descent
  FTO                                                     FTO                                                       rs11642841   16q12.2    53845487       A             0.45              3.E‐08      Voight *et al*.[15](#jdi12067-bib-0015){ref-type="ref"}     1.13 \[1.08‐1.18\]    European descent
  BCAR1                                                   CTRB1/B2                                                  rs7202877    16q23.1    75247245       T             0.89              4.E‐08      Morris *et al*.[24](#jdi12067-bib-0024){ref-type="ref"}     1.12 \[1.07--1.16\]   European descent
  SRR                                                     SRR                                                       rs391300     17p13.3    2216258        G             0.62              3.E‐09      Tsai *et al*.[13](#jdi12067-bib-0013){ref-type="ref"}       1.28 \[1.18‐1.39\]    Han Chinese
  HNF1B                                                   HNF1B                                                     rs4430796    17q12      36098040       G             0.28              2.E‐11      Li *et al*.[26](#jdi12067-bib-0026){ref-type="ref"}         1.19 \[1.13‐1.25\]    European descent
  LAMA1                                                   LAMA1                                                     rs8090011    18p11.31   7068462        G             0.38              8.E‐09      Perry *et al*.[22](#jdi12067-bib-0022){ref-type="ref"}      1.13 \[1.09‐1.18\]    European descent
  MC4R                                                    MC4R                                                      rs12970134   18q22      57884750       A             0.27              1.E‐08      Morris *et al*.[24](#jdi12067-bib-0024){ref-type="ref"}     1.08 \[1.05--1.11\]   European descent
  CILP2                                                   CILP2                                                     rs10401969   19p13.11   19407718       C             0.08              7.E‐09      Morris *et al*.[24](#jdi12067-bib-0024){ref-type="ref"}     1.13 \[1.09--1.18\]   European descent
  PEPD                                                    PEPD                                                      rs3786897    19q13.11   33893008       A             0.56              1.E‐08      Cho *et al*.[20](#jdi12067-bib-0020){ref-type="ref"}        1.10 \[1.07--1.14\]   East Asian
  FITM2/R3HDML                                            FITM2                                                     rs6017317    20q13.12   42946966       G             0.48              1.E‐11      Cho *et al*.[20](#jdi12067-bib-0020){ref-type="ref"}        1.09 \[1.07--1.12\]   East Asian
  HNF4A                                                   HNF4A                                                     rs4812829    20q13.12   42989267       A             0.29              3.E‐10      Kooner *et al*.[19](#jdi12067-bib-0019){ref-type="ref"}     1.09 \[1.06‐1.12\]    South Asian
  KRT18P48/DUSP9                                          DUSP9                                                     rs5945326    Xq28       152899922      A             0.79              3.E‐10      Voight *et al*.[15](#jdi12067-bib-0015){ref-type="ref"}     1.27 \[1.18‐1.37\]    European descent

Mapped and reported genes are arbitrarily denoted according to those shown in A Catalog of Published Genome‐Wide Association Studies (<http://www.genome.gov/gwastudies/index.cfm?pageid=26525384#searchForm>).

When \>1 studies have reported genome‐wide significant association at the relevant loci, we select one for each locus according to: (i) an ethnic group where the association was first reported; and (ii) the largest study in a given ethnic group.

At KCNQ1, although the association was first reported in Japanese (ref. [10](#jdi12067-bib-0010 jdi12067-bib-0011){ref-type="ref"}), it is not included in A Catalog of Published Genome‐Wide Association Studies and we show a Chinese study (ref. [13](#jdi12067-bib-0013){ref-type="ref"}) alternatively for reference.

On chromosome 3p25.2, although it did not attain a genome‐wide significance level in each study, the reproducible association has been shown for a candidate gene, PPARG, rs13081389, which is in linkage disequilibrium (*r*^2^ = 0.536) with rs1801282 (P12A, PPARG) in HapMap CEU. RAF,risk allele frequency; SNP, single nucleotide polymorphism.

At KCNQ1, significant association was also reported in European‐descent populations (ref. [15](#jdi12067-bib-0015){ref-type="ref"}), which is not in linkage disequilibrium with the one‐first reported in Japanese (ref. [10](#jdi12067-bib-0010 jdi12067-bib-0011){ref-type="ref"}).
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GWA studies are based on the principle of linkage disequilibrium (LD) at the population level. LD is the phenomenon in which alleles of two different loci (or genes) occur together more often than would be predicted by chance, indicating that the two alleles are physically close on the DNA strand. LD is created by evolutionary forces, such as mutation, drift and selection, and is broken down by recombination. A set of single nucleotide polymorphisms (SNPs) and mutations in strong LD tend to be inherited together by forming haplotypes. On carrying out GWA studies, we normally assay not all SNPs, but a subset of SNPs that can be chosen by considering the LD structure in a particular chromosomal region. If the pattern and strength of LD between the SNPs and mutations in the target region are similar, and the causal variants are commonly present among different populations (or different ethnic groups), the association in question is detectable at the SNP markers across the populations.

For the common type 2 diabetes‐associated variants, three features have to be noted. First, genetic impacts of individual variants or loci are generally modest; that is, allelic odds ratios (ORs) for type 2 diabetes are mostly in the range between 1.06 and 1.20, apart from several loci including *TCF7L2* (Figure [1](#jdi12067-fig-0001){ref-type="fig"}). This reflects the necessity of a large sample size in meta‐analysis to expose variants of smaller effect and more extreme risk allele frequency. Collectively, the most strongly associated variants at individual loci are estimated to explain approximately 10% of familial aggregation of type 2 diabetes[15](#jdi12067-bib-0015){ref-type="ref"}. Second, most of the variants identified to date are not in or near obvious candidate genes, but some are often located in the intergenic regions. This leads to the difficulty in estimating causal transcript; that is, the transcript responsible for mediating the effect of the associated variants, according to the location of association signals as discussed later. Third, although the number of variants is limited, there might be some population specificity in type 2 diabetes association. This has to be carefully interpreted by considering several possibilities; for example, the lack of power as a result of insufficient sample size and cross‐population differences in LD structure[34](#jdi12067-bib-0034){ref-type="ref"}. Although the majority of common variants have a consistent effect on the risk of type 2 diabetes across multiple ethnic groups[35](#jdi12067-bib-0035){ref-type="ref"}, some variants appear to exert more pronounced genetic effects in specific ethnic groups; for example, the association at *KLF14* is prominent in Europeans[15](#jdi12067-bib-0015 jdi12067-bib-0036){ref-type="ref"}, but not in East[20](#jdi12067-bib-0020){ref-type="ref"} and South[19](#jdi12067-bib-0019){ref-type="ref"} Asians.

![Risk allele frequencies and effect sizes of known susceptibility loci for type 2 diabetes (T2D), which have shown significant (*P* ≤ 5 × 10^−8^) association. Gene names are attached to the loci with odds ratio (OR) ≥1.2; they are not necessarily proven to be causal, but represent candidate transcripts on the basis of location and biological plausibility. Although a large part of associated loci were originally identified in populations of European descent, some were exclusively found or first reported in non‐European populations, which are differentially colored in the figure.](jdi-4-233-g1){#jdi12067-fig-0001}

Notably, it has been reported that most of the risk alleles for type 2 diabetes loci share a consistent pattern of decreasing frequencies along human migration from sub‐Saharan Africa to East Asia[37](#jdi12067-bib-0037){ref-type="ref"}. Such differential frequencies are hypothesized to be caused by the promotion of energy storage and usage appropriate to environments and inconsistent energy intake.

Along with the GWA meta‐analyses in individual populations, 'transethnic' meta‐analysis is currently being carried out, and will allow for a better chance to show novel susceptibility loci and pathophysiological pathways of type 2 diabetes, and might also facilitate the fine mapping of common causal variants by utilizing ethnic differences in LD structure[38](#jdi12067-bib-0038){ref-type="ref"}.

Overlap of Association Between Type 2 Diabetes and Glycemic Measures {#jdi12067-sec-0003}
====================================================================

GWA studies have also identified a number of genetic variants influencing glycemic measures (Tables S1--S3). When we focused on genome‐wide significant (*P* \< 5 × 10^−8^) association signals, we found that they partially overlapped between type 2 diabetes[9](#jdi12067-bib-0009 jdi12067-bib-0010 jdi12067-bib-0011 jdi12067-bib-0012 jdi12067-bib-0013 jdi12067-bib-0014 jdi12067-bib-0015 jdi12067-bib-0016 jdi12067-bib-0017 jdi12067-bib-0018 jdi12067-bib-0019 jdi12067-bib-0020 jdi12067-bib-0021 jdi12067-bib-0022 jdi12067-bib-0023 jdi12067-bib-0024 jdi12067-bib-0025 jdi12067-bib-0026){ref-type="ref"} and the glycemic measure traits -- fasting glu‐cose and insulin/homeostatic model assessment (HOMA)‐B (a parameter reflecting β‐cell function) and glycated hemoglobin (HbA~1c~) levels in the non‐diabetic population[12](#jdi12067-bib-0012 jdi12067-bib-0027 jdi12067-bib-0028 jdi12067-bib-0029 jdi12067-bib-0030 jdi12067-bib-0031 jdi12067-bib-0032){ref-type="ref"} (Figure [2](#jdi12067-fig-0002){ref-type="fig"}). As has been pointed out[39](#jdi12067-bib-0039){ref-type="ref"}, common variants associated with fasting plasma glucose levels do not necessarily influence the risk of type 2 diabetes and, by contrast, those associated with type 2 diabetes do not necessarily influence normal variation in fasting plasma glucose levels (48%, 11 of 23 loci overlapped), suggesting that a different set of genes influence physiological and pathophysiological variation in glucose homeostasis. Furthermore, from the viewpoint of disease mechanism and classification, of interest is the fact that there is some disparity in the list of associated loci between type 2 diabetes and fasting insulin/HOMA‐B (45%, 9 of 20 loci overlapped), and between type 2 diabetes and HbA~1c~ levels (38%, 5 of 13 loci overlapped). In the latter case, more than half of the detected loci likely influence HbA~1c~ levels through a non‐glycemic pathway, erythrocyte biology (e.g., iron homeostasis)[31](#jdi12067-bib-0031){ref-type="ref"}.

![A schematic representation of intertrait difference (or overlapping) for 41 diabetes‐related trait associated loci that have been reported in meta‐analyses of genome‐wide association studies[12](#jdi12067-bib-0012 jdi12067-bib-0027 jdi12067-bib-0028 jdi12067-bib-0029 jdi12067-bib-0030 jdi12067-bib-0031 jdi12067-bib-0032){ref-type="ref"}. The traits include fasting plasma glucose (FPG), insulin and its related‐traits (homeostasis model assessment of β‐cell function (HOMA‐B) and HOMA of insulin resistance), and glycated hemoglobin (HbA~1c~). Here, an associated locus is assumed to overlap between the traits when *P* ≤ 5 × 10^−8^ was concordantly attained. Underlined are the loci that have shown significant (*P* ≤ 5 × 10^−8^) association with type 2 diabetes; at three loci with asterisks -- ANK1,CDKAL1 and GRB14 -- variants associated with individual traits are not in linkage disequilibrium (*r*^2^ \< 0.3).](jdi-4-233-g2){#jdi12067-fig-0002}

Transition from Association Signal to Causal Mechanism {#jdi12067-sec-0004}
======================================================

Most loci associated with type 2 diabetes map to regulatory or intergenic regions of the genome, and in many cases the causal transcript remains undetermined. Surprisingly few of the genome‐wide association signals have mapped near strong biological candidates. Nevertheless, at some loci, it is inferred, based on a combination of supportive data; for example, coding variants (in particular, non‐synonymous SNPs), nearby biological candidates and *cis* expression quantitative trait loci (*cis*‐eQTLs), which regulate expression levels of messenger ribonucleic acid. Here, eQTLs that map to the approximate location of their gene‐of‐origin are referred to as *cis*‐eQTLs. Although eQTLs can be used to identify the downstream targets that are likely to be affected by associations detected in GWA studies, they still rely on genotyping methods, and therefore point to regions of LD rather than to individual SNPs. Accordingly, independent methods for identifying SNPs that overlap regulatory elements, such as transcription factor binding sites, are required. High‐throughput functional assays (e.g., ChIP‐seq[40](#jdi12067-bib-0040){ref-type="ref"}) can experimentally detect functional chromosomal regions, such as transcription factor binding sites, and the presence of SNPs in these regions can lead to differences in transcription factor binding between individuals[41](#jdi12067-bib-0041){ref-type="ref"}. Recently, the relevant experimental datasets have been generated and released to the public by the Encyclopedia of DNA Elements (ENCODE) Consortium[40](#jdi12067-bib-0040){ref-type="ref"}, which will help identify functional SNPs associated with type 2 diabetes and their potential causal transcript.

Although we can estimate a single or a few target genes for individual loci by referring to the data for experiments *in vitro*; for example, the ENCODE data, biological function remains largely unknown for a substantial part of such target genes. So far, just 17% (12 of 70 loci) have been proven to show type 2 diabetes‐related phenotypes in their knock‐out mice experiments *in vivo* (Table [2](#jdi12067-tbl-0002){ref-type="table-wrap"}). Besides, three target genes -- *GCK*,*HNF1B* and *HNF4A* -- overlap with causal genes for MODY, where *GCK*[42](#jdi12067-bib-0042){ref-type="ref"} and *HNF4A*[43](#jdi12067-bib-0043){ref-type="ref"} knock‐out mice show hyperglycemia and glucose intolerance, respectively.

###### Genome‐wide association study‐identified positional candidate genes for type 2 diabetes, with supportive phenotypes observed in knock‐out mice

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene        MGI ID    Phenotypes observed in knock‐out mice                                                                                                                                                                                                        Reference (PMID no.)                                   Other associated trait identified via GWA study[a](#jdi12067-note-0006){ref-type="fn"}
  ----------- --------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------ ----------------------------------------------------------------------------------------
  *GRB14*     1355324   Improved glucose tolerance, insulin levels decreased, increased incorporation of glucose into glycogen in the liver and skeletal muscle of males. Both males and females showed a decrease in body size.                                     Cooney GJ, 2004 *EMBO J* (14749734)                    Waist‐hip ratio\
                                                                                                                                                                                                                                                                                                                            \
                                                                                                                                                                                                                                                                                                                            Blood pressure

  *IRS1*      99454     Impaired glucose tolerance, mild insulin and IGF‐1 resistance; 50% reductions in body weight at birth and at 4 months‐of‐age.\                                                                                                               Araki E, 1994 *Nature* (7526222)                       Visceral adipose tissue/subcutaneous adipose tissue ratio\
                        \                                                                                                                                                                                                                                                                                                   \
                        Homozygotes: lethal.                                                                                                                                                                                                                                                                                Adiponectin levels

  *PPARG*     97747     Heterozygotes: greater β‐cell proliferation, enhanced leptin secretion, and resistance to high‐fat diet‐induced adipocyte hypertrophy and insulin resistance.                                                                                Kubota N, 1999 *Molecular Cell* (10549291)             Plasminogen activator inhibitor type 1 levels

  *WFS1*      1328355   Decreased pancreatic beta cells, impaired glucose tolerance, decreased body weight and abnormal behavior associated with increased sensitivity to stress.                                                                                    Ishihara H, 2004 *Hum Mol Genet* (15056606);\          N/A
                                                                                                                                                                                                                                                                     \                                                      
                                                                                                                                                                                                                                                                     Riggs AC, 2005 *Diabetologia* (16215705)               

  *SLC30A8*   2442682   Reduced islet zinc levels, insulin levels decreased and glucose‐stimulated insulin secretion decreased.                                                                                                                                      Lemaire K, 2009 *Proc Natl Acad Sci USA* (19706465)    Asthma

  *GLIS3*     2444289   Postnatal lethality associated with neonatal diabetes and polycystic kidney disease.                                                                                                                                                         Kang HS, 2009 *Mol Cell Biol* (19273592);\             Type 1 diabetes
                                                                                                                                                                                                                                                                     \                                                      
                                                                                                                                                                                                                                                                     Watanabe N, 2009 *FEBS Lett* (19481545)                

  *FTO*       1347093   Body weight decreased, adipose tissue decreased and body fat decreased; metabolism increased, serum lipids increased and serum glucagon increased.                                                                                           Fischer J, 2009 *Nature* (19234441)                    Body mass index\
                                                                                                                                                                                                                                                                                                                            \
                                                                                                                                                                                                                                                                                                                            Waist circumference\
                                                                                                                                                                                                                                                                                                                            \
                                                                                                                                                                                                                                                                                                                            Osteoarthritis\
                                                                                                                                                                                                                                                                                                                            \
                                                                                                                                                                                                                                                                                                                            Menarche

  *MC4R*      99457     Hyperglycemia and weight gain.                                                                                                                                                                                                               Huszar D, 1997 Cell (9019399)                          Body mass index\
                                                                                                                                                                                                                                                                                                                            \
                                                                                                                                                                                                                                                                                                                            Waist circumference\
                                                                                                                                                                                                                                                                                                                            \
                                                                                                                                                                                                                                                                                                                            Height

  *HNF4A*     109128    Nullizygous embryos: delayed growth and lethality.\                                                                                                                                                                                          Gupta RK, 2005 J Clin Invest (15761495);\              C‐reactive protein\
                        \                                                                                                                                                                                                                                            \                                                      \
                        Conditional deletion in pancreatic beta cells: hyperinsulinemia and impaired glucose tolerance.                                                                                                                                              Pearson ER, 2007 *PLoS Med* (17407387)                 Ulcerative colitis

  *GCKR*      1096345   Reduced glucokinase protein levels and activity in the liver and altered glucose homeostasis.                                                                                                                                                Farrelly D, 1999 *Proc Natl Acad Sci USA* (10588736)   Total protein/albumin levels\
                                                                                                                                                                                                                                                                                                                            \
                                                                                                                                                                                                                                                                                                                            Sex hormone‐binding globulin levels\
                                                                                                                                                                                                                                                                                                                            \
                                                                                                                                                                                                                                                                                                                            Phospholipid levels\
                                                                                                                                                                                                                                                                                                                            \
                                                                                                                                                                                                                                                                                                                            Platelet counts\
                                                                                                                                                                                                                                                                                                                            \
                                                                                                                                                                                                                                                                                                                            C‐reactive protein\
                                                                                                                                                                                                                                                                                                                            \
                                                                                                                                                                                                                                                                                                                            Crohn\'s disease\
                                                                                                                                                                                                                                                                                                                            \
                                                                                                                                                                                                                                                                                                                            Urate levels\
                                                                                                                                                                                                                                                                                                                            \
                                                                                                                                                                                                                                                                                                                            Chronic kidney disease

  *GCK*       1270854   Mild hyperglycemia in heterozygous mice and extreme hyperglycemia and embryonic to postnatal ethality in homozygous mice.                                                                                                                    Bali D, 1995 *J Biol Chem* (7665557)                   N/A

  *CDKAL1*    1921765   Conditional deletion in pancreatic beta cells: impaired tRNA Lys modification, reduction of glucose‐stimulated proinsulin synthesis.Global deletion: body weight decresed, glucose intolerance manifested after 20 weeks of high‐fat diet.   Wei FY, 2011 *J Clin Invest* (21841312);\              Body mass index\
                                                                                                                                                                                                                                                                     \                                                      \
                                                                                                                                                                                                                                                                     Okamura T, 2012 *PLoS One* (23173044)                  Birth weight\
                                                                                                                                                                                                                                                                                                                            \
                                                                                                                                                                                                                                                                                                                            Crohn\'s disease
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Phenotype traits, with which genome‐wide association (GWA) studies identified significant association at the corresponding gene locus are listed, except for lipid and glucose‐related traits. IGF‐1, insulin‐like growth factor 1; MGI, mouse genome informatics.

John Wiley & Sons, Ltd

Despite significant enrichment for regulatory (and non‐coding) sequence variants in disease‐associated regions, there are some cases where substantial statistical and biological evidence can support particular coding sequence variants as causal. For example, the type 2 diabetes association signal on chromosome 2p23 was shown to derive from a common non‐synonymous SNP rs1260326, P446L, in *GCKR,* which is one of 17 genes mapped to the 420‐kb interval of association in tight LD[44](#jdi12067-bib-0044){ref-type="ref"}. In addition to the strong candidacy of *GCKR* in glucose metabolism, functional characterization *in vitro* showed that P446L could explain a mutational mechanism for the reported counterintuitive association with increased triglycerides and reduced glucose levels on 2p23.

New Biology Arising from Gwa Study Discoveries {#jdi12067-sec-0005}
==============================================

β‐Cell Dysfunction {#jdi12067-sec-0006}
------------------

Regarding the pathogenesis of type 2 diabetes, there has been a long‐standing debate over the relative roles of insulin secretory defects and insulin resistance. In this context, of interest is the fact that a large part of the type 2 diabetes‐risk loci exert their primary effects on disease risk through reduced insulin secretion rather than increased insulin resistance in the general population[15](#jdi12067-bib-0015 jdi12067-bib-0045){ref-type="ref"}. Genes implicated in cell‐cycle regulation are overrepresented within type 2 diabetes‐associated regions; this is consistent with the notion that control of β‐cell mass is a key component of disease risk[15](#jdi12067-bib-0015){ref-type="ref"}.

However, when we look at genetic loci associated with proinsulin levels, there are divergent directions of association between type 2 diabetes risk and proinsulin levels[46](#jdi12067-bib-0046){ref-type="ref"}. Similar to the relationship between type 2 diabetes and fasting plasma glucose[39](#jdi12067-bib-0039){ref-type="ref"}, the loci are partially overlapped between the traits. Among the loci associated with proinsulin, three loci -- *TCF7L2*,*C2CD4A* and *SLC30A8* -- were significantly associated with type 2 diabetes in a manner consistent with established epidemiological relationships; that is, higher proinsulin levels are associated with impaired β‐cell function, insulin resistance and risk of type 2 diabetes[47](#jdi12067-bib-0047 jdi12067-bib-0048){ref-type="ref"}. In contrast, one locus -- *ARAP1* -- showed trait association in a counterinstinctive direction. Thus, both disproportionate elevations and reductions in proinsulin can indicate β‐cell dysfunction at individual loci[46](#jdi12067-bib-0046){ref-type="ref"}.

Efforts to show that the genes mapping close to susceptibility loci are enriched for particular pathways or processes have not been particularly rewarding so far, apart from a few instances (e.g., cell‐cycle regulation)[15](#jdi12067-bib-0015){ref-type="ref"}. This indicates the possibility that type 2 diabetes is highly heterogeneous, and/or existing biological knowledge is as yet insufficient to capture key fundamental aspects of its pathophysiology through database search. Although it is challenging to establish the biological mechanism at each associated locus, a combination of experimental and bioinformatic approaches will help understand the broad processes of disease pathogenesis by integrating a number of loci identified in the unbiased genome‐wide approach.

Epigenetics {#jdi12067-sec-0007}
-----------

The evidence for familial aggregation of type 2 diabetes comes from a number of epidemiological studies; parental type 2 diabetes has been reported to give rise to an approximately threefold increase in disease risk in the offspring[49](#jdi12067-bib-0049){ref-type="ref"}. The familial aggregation might reflect epigenetic mechanisms, such as the fetal origins hypothesis[50](#jdi12067-bib-0050){ref-type="ref"}, in addition to genetic influences and shared family environment. As an approach to addressing this issue, Kong *et al*.[51](#jdi12067-bib-0051){ref-type="ref"} examined the impact of parental origin on disease associations in previous GWA studies and identified parental‐origin‐specific associations with type 2 diabetes at variants located in the known imprinted region on chromosome 11p15. Here, the allele that confers risk when paternally inherited (odds ration \[OR\] = 1.41, *P *= 4.3 × 10^−9^) is protective when maternally transmitted (OR = 0.87, *P *= 0.02) and also correlated with decreased methylation of CTCF‐binding site at 11p15[51](#jdi12067-bib-0051){ref-type="ref"}.

A growing body of data has established that the molecular basis of metabolic programming involves DNA methylation and histone modifications[52](#jdi12067-bib-0052){ref-type="ref"}. To date, relatively few studies have explored the epigenetic component to the development of type 2 diabetes, with most of them focusing on the methylation status of selected C‐phosphate‐G (CpG) sites in candidate genes. Because of the relatively high cost and procedural complexity of epigenetic analysis, as well as tissue differences in methylation profile, there are few convincing results that support the contribution of epigenetics to disease pathogenesis at present. To make the situation intricate, it has been reported at *FTO*, one of the principal risk loci for obesity and type 2 diabetes, that epigenetic effects might, at least in part, be driven by underlying variation in the DNA sequence[53](#jdi12067-bib-0053){ref-type="ref"}. That is, methylation levels at a CpG site in the first intron of *FTO* were correlated with a genotype at nearby disease‐associated SNPs. This could be simply regarded as a subset of genetic association signals at which the downstream effects are mediated by genotype‐dependent changes in local DNA methylation. However, it remains unclear whether methylation by itself constitutes the causal link between the *FTO* risk allele and type 2 diabetes[54](#jdi12067-bib-0054){ref-type="ref"}.

Pleiotropy {#jdi12067-sec-0008}
----------

GWA studies of type 2 diabetes have provided substantial evidence of pleiotropy; the same variants are associated with multiple traits (Table [3](#jdi12067-tbl-0003){ref-type="table-wrap"}), providing clues to the common biological pathways involved. For example, at *ADCY5* and *CDKAL1*, the birth weight‐lowering allele was associated with a greater risk of type 2 diabetes[55](#jdi12067-bib-0055){ref-type="ref"}. This is consistent with the fetal insulin hypothesis[56](#jdi12067-bib-0056){ref-type="ref"}; that is, common genetic variation influencing insulin secretion or action, both in prenatal development and adult life, could partly explain epidemiological correlations between lower birth weight and type 2 diabetes. Here, of particular note is the fact that the type 2 diabetes risk allele at *CDKAL1* also showed a significant association with lower body mass index (BMI) in adult East Asians[57](#jdi12067-bib-0057 jdi12067-bib-0058){ref-type="ref"}, indicating the possibility of sustained, reduced insulin secretion in adulthood. In this line, despite the clustering of type 2 diabetes and obesity in metabolic syndrome, the directions of association appear to be divergent at susceptibility loci. A positive correlation has been shown between type 2 diabetes risk and higher BMI for a few obesity‐associated loci; for example, *FTO* and *MC4R*, whereas an inverse correlation between the traits has been found for several type 2 diabetes‐associated loci including *CDKAL1*[59](#jdi12067-bib-0059){ref-type="ref"}. This reveals further complexity in biological pathways that influence metabolic impairments.

###### List of gene variants showing potential pleiotropic effects on type 2 diabetes and other traits

  Trait                                Nearby gene(s)   Variant      LD coefficient, *r*^2^ (HapMap panel)   Type 2 diabetes‐associated SNP[a](#jdi12067-note-0008){ref-type="fn"}   Effect on the trait[b](#jdi12067-note-0009){ref-type="fn"}   Reported study
  ------------------------------------ ---------------- ------------ --------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------ -----------------------------------
  Adiponectin levels                   *IRS1*           rs925735     0.648 (CEU)                             rs7578326                                                               ↓                                                            Dastani Z, 2012 *PLoS Genet*
  Adiponectin levels                   *PEPD*           rs731839     0.345 (CEU) 0.894 (JPT+CHB)             rs3786897 (East Asians)                                                 ↓                                                            Dastani Z, 2012 *PLoS Genet*
  Birthweight                          *ADCY5*          rs9883204    0.782 (CEU)                             rs11708067                                                              ↓                                                            Freathy RM, 2010 *Nat Genet*
  Birthweight                          *CDKAL1*         rs6931514    1.000 (CEU)                             rs7766070                                                               ↓                                                            Horikoshi M, 2012 *Nat Genet*
  Height                               *IGF2BP2*        rs720390     0.491 (CEU)                             rs4402960                                                               ↑                                                            Lango Allen H, 2010 *Nature*
  Height                               *JAZF1*          rs1635852    1.000 (CEU)                             rs849134                                                                ↑                                                            Johansson A, 2008 Hum *Mol Genet*
  Height                               *C2CD4A*         rs7178424    0.422 (CEU) 0.082 (JPT+CHB)             rs7172432 (Japanese)                                                    Unknown                                                      Lango Allen H, 2010 *Nature*
  Height                               *MC4R*           rs17782313   0.813 (CEU)                             rs12970134                                                              ↑                                                            Lango Allen H, 2010 *Nature*
  Type 1 diabetes                      *GLIS3*          rs7020673    0.902 (CEU) 0.705 (JPT+CHB)             rs7041847 (East Asians)                                                 ↑                                                            Barrett JC, 2009 *Nat Genet*
  Type 1 diabetes                      *RASGRP1*        rs8035957    0.733 (CEU) 0.414 (JPT+CHB)             rs7403531 (Chinese)                                                     Unknown                                                      Grant SF, 2008 *Diabetes*
  Multiple sclerosis                   *HHEX*           rs7923837    0.699 (CEU)                             rs5015480                                                               ↑                                                            Sawcer S, 2011 *Nature*
  Coronary heart disease               *SRR/SMG6*       rs216172     0.552 (CEU) 0.588 (JPT+CHB)             rs391300 (Chinese)                                                      ↓                                                            Schunkert H, 2011 *Nat Genet*
  Prostate cancer/endometrial cancer   *HNF1B*          rs4430796    1.000 (CEU)                             rs4430796                                                               ↓                                                            Gudmundsson J, 2007 *Nat Genet*

In the table, we list type 2 diabetes‐associated variants, whose proxy single nucleotide polymorphisms (SNPs; *r*^2^* *\> 0.4) also show significant association with other traits.

In some cases, significant type 2 diabetes‐association was reported only in East Asian populations, whereas the association with other trait(s) was found in populations of European‐descent.

The direction of association was estimated by considering the linkage disequilbrium (LD) information on haplotypes except for two loci (C2CD4A and RASGRP1), where LD was too modest.

John Wiley & Sons, Ltd

Several studies have examined the association of type 2 diabetes variants with cardiovascular outcome, assuming some causal association between the diseases[60](#jdi12067-bib-0060 jdi12067-bib-0061){ref-type="ref"}. A potentially shared association has been noted at a genomic region near the *SRR* locus, where the minor allele C of rs216172 is positively associated with coronary heart disease (CHD) risk (OR = 1.07) in the population of European‐descent[62](#jdi12067-bib-0062){ref-type="ref"}, and the minor allele A of rs391300 is inversely associated with type 2 diabetes (OR = 0.78) in the Chinese population[13](#jdi12067-bib-0013){ref-type="ref"}; two SNPs near *SRR* are in LD (*r*^2^ = 0.552 in the HapMap population of European ancestry and 0.588 in the HapMap population of East Asian ancestry). At another region on chromosome 9p21 near *CDKN2A/B*, a significant association has been identified for CHD[62](#jdi12067-bib-0062){ref-type="ref"} and type 2 diabetes[15](#jdi12067-bib-0015 jdi12067-bib-0019 jdi12067-bib-0020){ref-type="ref"}, as well as several other diseases. The 9p21 region is under intense research[63](#jdi12067-bib-0063){ref-type="ref"}, as independent functional variants are likely to exist within this region and could be associated with individual diseases. Apart from these two loci, the results for associations between the individual diabetes‐predisposing genetic variants and CHD risk appear to be inconsistent. A few recent studies, however, have shown that, when tested in aggregate using a genetic risk score, the overall genetic predisposition to type 2 diabetes is associated with an increased risk of CHD[60](#jdi12067-bib-0060 jdi12067-bib-0061){ref-type="ref"}.

GWA studies have provided evidence for an interrelation between type 2 diabetes and prostate cancer[64](#jdi12067-bib-0064){ref-type="ref"}. Observational studies have consistently shown an inverse association between the two diseases, with meta‐analysis risk ratios ranging from 0.84 to 0.91[65](#jdi12067-bib-0065 jdi12067-bib-0066){ref-type="ref"}. In good accordance with this, one shared genomic region at *HNF1B* has been highlighted in GWA scan[67](#jdi12067-bib-0067){ref-type="ref"}, where the major allele A of rs4430796 is positively associated with prostate cancer (OR = 1.22) and inversely associated with type 2 diabetes risk (OR = 0.91). Although the biological mechanism underlying such paradoxical associations is poorly understood, it is hypothesized that in type 2 diabetes patients, metabolic status might move gradually from hyperinsulinemia to endogenous insulin deficiency, thus blunting oncogenic action of insulin in the prostate[68](#jdi12067-bib-0068){ref-type="ref"}. The GWA results have further indicated a direct association between diabetes risk variants other than *HNF1B* and prostate cancer risk plus the lack of significant evidence supporting the potential for a type 2 diabetes phenotype to mediate the genetic effect of *HNF1B*[64](#jdi12067-bib-0064){ref-type="ref"}.

Potential of Translational Advances {#jdi12067-sec-0009}
===================================

Missing Heritability {#jdi12067-sec-0010}
--------------------

It has been argued that susceptibility loci identified through GWA studies explain only a small proportion of heritability (approximately 5--10%) for type 2 diabetes. This discrepancy, termed missing heritability[69](#jdi12067-bib-0069){ref-type="ref"}, has been attributed to a number of factors including insufficient survey of rare variants and structural variants, inaccuracy of current heritability estimates (e.g., inflation because of shared family environment), and epigenetics. It remains to be defined whether complex traits are truly affected by thousands of variants with small effect, but recent analysis of GWA study data using a computational technique has suggested that many hundreds of common weakly‐associated variants might be sufficient to account for the majority of heritability -- approximately 50% of overall trait variance for type 2 diabetes[70](#jdi12067-bib-0070){ref-type="ref"}, in accordance with the assumption of 'hidden' heritability[71](#jdi12067-bib-0071){ref-type="ref"}. Along this, given the strong interplay of genetics, epigenetics and environment, partitioning individual propensity to develop type 2 diabetes is not feasible.

Personalized Medicine {#jdi12067-sec-0011}
---------------------

Successful applications of personalized medicine in the clinical management of diabetes patients are restricted to the rare, monogenic forms of disease. For example, it is known that MODY patients with *HNF1A* mutations respond particularly well to sulphonylurea treatment[72](#jdi12067-bib-0072){ref-type="ref"}. Similar efforts have been made for common forms of type 2 diabetes, in two principal areas of personalized medicine -- molecular prediction (or diagnosis) and personalized therapy. To provide improved predictive power over conventional risk factors, genetic testing must be sensitive and specific in discriminating subjects who will develop the disease on follow up from those who will not[73](#jdi12067-bib-0073){ref-type="ref"}. In this line, it has been recognized that genetic variants so far identified do not substantially improve the discriminative accuracy of disease prediction based on conventional risk factors[74](#jdi12067-bib-0074 jdi12067-bib-0075){ref-type="ref"}. Even genetic models incorporating thousands of additional putative common variants are likely to offer limited improvement[73](#jdi12067-bib-0073 jdi12067-bib-0076){ref-type="ref"}. Although some studies have shown that molecular prediction is slightly more effective in certain patient groups, such as the young[74](#jdi12067-bib-0074 jdi12067-bib-0077){ref-type="ref"}, the discriminative accuracy still falls short of the clinical utility at the individual level. At the group level, in contrast, risk stratification is achievable to some extent by using a genetic risk score (GRS); this is an integrated summary of genetic risk from all the different variants in the genome that GWA studies have identified as predisposing to the disease. The GRS thus calculated has the capacity to highlight patient groups at the top end of the risk distribution[78](#jdi12067-bib-0078 jdi12067-bib-0079){ref-type="ref"}. A higher GRS was shown to be associated with indices of diminished β‐cell function and incidence of diabetes during follow up, gaining predictive ability in comparison with clinical characteristics alone[78](#jdi12067-bib-0078){ref-type="ref"}. Furthermore, lifestyle interventions appear to be effective even among individuals at highest genetic risk[78](#jdi12067-bib-0078 jdi12067-bib-0080){ref-type="ref"}. Therefore, it is worth testing whether targeting such high‐risk groups for an earlier preventative intervention strategy is beneficial.

From the viewpoint of individual therapeutic utility, pharamacogenetic studies in common forms of type 2 diabetes have not yet achieved remarkable progress, apart from a few successes in the candidate gene approach; for example, positive associations between variation in sulfonylurea response and genotype at the *ABCC8/KCNJ11* and *TCF7L2* loci[81](#jdi12067-bib-0081 jdi12067-bib-0082){ref-type="ref"}. It is assumed that individual loci affecting antidiabetes drug response exert modest effects, and hence large‐scale pharamacogenetic GWA studies are required to identify novel susceptibility gene variants.

Also, in terms of clinical management, genetics of diabetic microvascular complications -- retinopathy, nephropathy and neuropathy -- is an issue of great interest. Although a number of suggestive loci have been nominated through candidate gene approach or GWA study[83](#jdi12067-bib-0083 jdi12067-bib-0084){ref-type="ref"}, none have attained genome‐wide significant association with the disease, partly because of the lack of statistical power. Given the substantial genetic heterogeneity, future large‐scale consortium‐based studies are warranted.

Perspective {#jdi12067-sec-0012}
===========

Remarkable progress has been made in the genetics of type 2 diabetes in the past 5 years, principally through GWA studies. This proceeds with the rapid technological advances in 'the era of big data', which will further enable the sequencing of entire genomes in large samples at affordable costs. We expect that a larger list of associated loci can be discovered in the next few years, thanks to unprecedented global collaboration involving different ethnic groups. Under such circumstances, we have just begun to face new challenges -- elucidation of multifaceted (i.e., molecular, cellular and physiological) mechanistic insights into disease biology by considering interaction with environment[85](#jdi12067-bib-0085){ref-type="ref"} -- before clinical translation.
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**Table S1** \| List of loci regulating fasting plasma glucose level with suggestive or significant evidence for association (*P* \< 1E‐5)

**Table S2** \| List of loci regulating insulin‐related traits with suggestive or significant evidence for association (*P* \< 1E‐5)

**Table S3** \| List of loci regulating glycated hemoglobin level with suggestive or significant evidence for association (*P* \< 1E‐5)
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Click here for additional data file.
